Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 30140912.
- Also identified by DOI 10.1001/jamadermatol.2018.2510 and PMC identifier 6233739.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This randomized clinical trial assesses whether treatment with the neurokinin 1 receptor antagonist aprepitant decreases pruritus vs placebo in patients with Sézary syndrome.
Medical subject headings
- Aprepitant
- Neurokinin-1 Receptor Antagonists
- Pruritus
- Sezary Syndrome
- Skin Neoplasms